Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of piceatannol-3'-O-beta-D-glucopyranoside in treatment of small intestine ischemia/reperfusion injury

A technology of ischemia-reperfusion and tristilbene, which is applied to the application field of tristilbene in the treatment of small intestine ischemia-reperfusion injury, and can solve the problems of unsatisfactory effect and the like

Pending Publication Date: 2021-05-18
DALIAN MEDICAL UNIVERSITY
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the clinical treatment methods for small intestinal ischemia-reperfusion injury mainly include ischemic preconditioning, improving microcirculation, anti-apoptosis, anti-cytokine and inflammatory mediator injury, etc., but the effect is not satisfactory.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of piceatannol-3'-O-beta-D-glucopyranoside in treatment of small intestine ischemia/reperfusion injury
  • Application of piceatannol-3'-O-beta-D-glucopyranoside in treatment of small intestine ischemia/reperfusion injury
  • Application of piceatannol-3'-O-beta-D-glucopyranoside in treatment of small intestine ischemia/reperfusion injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] The therapeutic use of the present invention is proved by the following experiments:

[0021] Materials and methods

[0022] Drugs and Reagents

[0023] Tristilbene was extracted from Rheum officinalis in Lhasa, and the purity was higher than 98.0%. TNF-α ELIASA kit was purchased from Shanghai Jianglai Biotechnology Co., Ltd. (Shanghai, China); eNOS ELIASA kit and T-SOD biochemical kit were purchased from Elabscience Company (Wuhan, China). MPO and MDA biochemical kits were purchased from Nanjing Jiancheng Biological Co., Ltd. (Nanjing, China).

[0024] experimental animals

[0025] Male Kunming mice, (25g±2g, Liaoning Changsheng Biotechnology Co., Ltd., Benxi, China). Raised in a constant temperature (20±2°C) environment, 12h cycle light, fed with regular diet and water. The experimental protocol was approved by the Animal Experiment Ethics Committee of Dalian Medical University (ethics number: AEE20024).

[0026] surgical procedure

[0027] The mice were fasted...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of piceatannol-3'-O-beta-D-glucopyranoside in treatment of small intestine mucosa injury and intestinal inflammatory cell infiltration caused by ischemia reperfusion. Experimental results show that by virtue of the piceatannol-3'-O-beta-D-glucopyranoside, the yield of malondialdehyde (MDA) and the activity of myeloperoxidase (MPO) in intestinal tissues after ischemia / reperfusion can be remarkably reduced, the expression level of tumor necrosis factor-alpha (TNF-alpha) can be reduced, the expression level of endothelial nitric oxide synthase (eNOS) can be increased, the activity of total-superoxide dismutase (T-SOD) can be remarkably improved, and intestinal interstitial hemorrhage and small intestine mucosa defect are relieved. The piceatannol-3'-O-beta-D-glucopyranoside can effectively treat the small intestine ischemia reperfusion injury, and a basis is provided for application of the piceatannol-3'-O-beta-D-glucopyranoside in treatment of small intestine ischemia reperfusion related diseases.

Description

technical field [0001] The present invention specifically relates to the use of tristilbene glycoside in the treatment of small intestine ischemia-reperfusion injury. Background technique [0002] Tristilbene is a compound extracted from the rhizome of Rhubarb Lhasa, and its structural name is (E)-1-(3,5-dihydroxyphenyl)-2-(3-hydroxy-4-O-β-D- Glucopyranose (phenyl)ethylene, or 3,5,3',4'-tetrahydroxystilbene-3'-O-β-glucose. [0003] [0004] 【English name】Piceatannol-3'-O-β-D-glucopyranoside [0005] 【Molecular formula】C 20 h 22 o 9 [0006] 【Molecular Weight】406.13 [0007] Stilbenes are a class of derivatives with stilbene as the parent structure. Stilbene substances widely exist in Liao family plants in nature. Current studies have shown that trizaperone has a variety of pharmacological activities, mainly including anti-inflammatory, anti-oxidation, scavenging oxygen free radicals, anti-tumor, anti-virus and antibacterial [1,2] . According to reports, trizaper...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7034A61P9/10A61P1/00A61P29/00A61P7/04
CPCA61K31/7034A61P9/10A61P1/00A61P29/00A61P7/04
Inventor 王玉林李丽吴真真
Owner DALIAN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products